Sickle cell disease clinical trials

Explore recruiting sickle cell disease clinical trials.

Recruiting sickle cell disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sickle cell disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease

Spain, France, Netherlands, Belgium, Greece, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease

France, Italy, Netherlands, Belgium, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants with Sickle Cell Disease to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability, pH and Food Effect, and Preliminary Efficacy of BMS-986470

France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Evaluation of safety and efficacy of mitapivat sulfate in adult patients with sickle cell disease

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy

France, Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

Sickle cell disease trials by city

Sickle cell disease in Toronto Sickle cell disease in Vancouver Sickle cell disease in Montreal Sickle cell disease in Calgary Sickle cell disease in Edmonton Sickle cell disease in Ottawa Sickle cell disease in Winnipeg Sickle cell disease in Quebec City Sickle cell disease in Hamilton Sickle cell disease in Kitchener Sickle cell disease in London Sickle cell disease in Halifax Sickle cell disease in New York Sickle cell disease in Los Angeles Sickle cell disease in Chicago Sickle cell disease in Houston

Other conditions

Endometrial cancer Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease HIV Hepatitis B Hepatitis C COVID-19 Influenza RSV Anemia Hemophilia Thalassemia Chronic pain Low back pain Smoking cessation Tinnitus Hearing loss Chronic fatigue syndrome Obesity Type 2 diabetes Type 1 diabetes